**C3RN News Summary – June 10, 2019**

Research

1. In an opinion piece published in *Palliative and Supportive Care* the author notes that “cannabis and its constituents have…been reported to be useful in assisting with sleep, mood, and anxiety. Despite significant in vitro and animal model evidence supporting the anti-cancer activity of individual cannabinoids-particularly THC and cannabidiol (CBD)-clinical evidence is absent. A single intervention that can assist with nausea, appetite, pain, mood, and sleep is certainly a valuable addition to the palliative care armamentarium.” The author concludes that “oncologists and palliative care providers should recommend this botanical remedy to their patients to gain first-hand evidence of its therapeutic potential despite the paucity of results from randomized placebo-controlled clinical trials to appreciate that it is both safe and effective and really does not require a package insert.”

[June 3, 2019: University of California San Francisco](https://link.springer.com/article/10.1007%2Fs11864-019-0659-9)

2. In a study examining threat responsiveness in adolescent populations researchers found that “increasing levels of CUD symptomatology were associated with *decreased* responding to *looming stimuli* within regions, including rostral frontal and fusiform gyrus as well as the amygdala,” and concluded “these data indicate that CUD in particular is associated with a decrease in responsiveness to the looming threat cue possibly relating to the putative neurotoxic impact of cannabis abuse.”

[June 6, 2019: Boys Town National Research Hospital](https://www.liebertpub.com/doi/10.1089/cap.2019.0004)

Industry News

3. An article talking about the future of CBD, regulations and the FDA notes that “A 2017 study found that 26% and 43% of CBD products tested had lower and higher amounts of the compound, respectively, than were listed on their labels.”

[June 6, 2019: Time](https://time.com/5601977/united-states-government-cbd/)

4. An article by CNBC talks about the rise of cannabis use in older populations, and while describing relevant research notes that “many study participants said they had problems accessing medical cannabis, adding that there was a lack of education among physicians when it comes to treating ailments with marijuana. Some of the study’s participants didn’t ask their doctors about it because of the stigma.”

[June 7, 2019: CNBC](https://www.cnbc.com/2019/06/07/marijuana-use-among-baby-boomers-rose-tenfold-over-decade-as-seniors-seek-out-pot-for-medical-treatment.html)

5. Complications with legal CBD products are discussed in an article by ABC Action News. The article describes the experience someone has taking CBD products. The author states “she was taking CBD after suffering from seizures and migraines. She was told the product she was using had no THC in it; she even had lab toxicology reports from the company to prove it. So she was completely caught off guard after a drug test revealed positive results for THC.”

[June 9th, 2019: ABC Action News](https://www.abcactionnews.com/news/national/can-using-cbd-products-cost-someone-their-job-heres-what-you-need-to-know)